Bristol Myers Bags RayzeBio in $4.1B Cancer Fight Pact
Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
- Latest
- Trending
Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Emeren Group has launched a $10M accelerated stock repurchase program, aiming to increase shareholder value and strengthen its position in ...
Goldman Sachs raises price target on Cloudflare to $89 as company reports positive quarterly performance, including increased ACV and RPO. ...
French President Macron appoints Gerard Mestrallet as special envoy to rival China's Belt and Road initiative with a major railway ...
Unilever CEO Hein Schumacher receives support for the company's strategy from billionaire activist Nelson Peltz. Peltz's endorsement and alignment with ...
London-based transport-systems group, Journeo, predicts its full-year performance to meet market expectations with strong organic growth.
Gartner has identified key trends that will affect technology providers in 2024. These include the rise of Generative AI, the ...
Microsoft faces backlash after announcing a significant reduction in its gaming division workforce, raising concerns about competition and antitrust laws ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.